1-Alpha-hydroxy vitamin D in dialysis bone disease: Radiological changes after 6 and 12 months of treatment

P. J A Robinson, G. S. Walker, Munro Peacock, M. S F McLachlan, A. M. Davison

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Biochemical, radiological and histological indicators of dialysis bone disease were studied before, 6 months (58 patients) and 12 months (48 patients) after starting treatment with 1α-OH D3. Radiographic healing of subperiosteal erosions was seen after 6 months in 60% and after 12 months in 77% of affected patients. Radiographic improvement, however, was not significantly related to reductions in resorptive surfaces seen on quantitative bone histology, nor to changes in plasma concentrations of immunoreactive parathyroid hormone. Metastatic calcification appeared or increased in 43% of patients after 6 months and 52% after 12 months. Periosteal new bone developed or increased in 14% of patients after 6 months and 17% after 12 months. Both metastatic calcification and periosteal new bone formation were associated with high plasma phosphate concentrations, but not with plasma calcium, alkaline phosphatase or parathyroid hormone concentrations. Treatment with 1α-OH D3 produces radiological improvement in the majority of patients with dialysis bone disease, but the lack of correlation with histological changes confirms the need for regular radiographic examination. Metastatic calcification and periosteal new bone formation probably represent toxicity of 1α-OH D3, but may be minimised by phosphate restriction.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalClinical Radiology
Volume33
Issue number1
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Bone Diseases
Vitamin D
Dialysis
Parathyroid Hormone
Osteogenesis
Therapeutics
Phosphates
Bone and Bones
Alkaline Phosphatase
Histology
Calcium

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

1-Alpha-hydroxy vitamin D in dialysis bone disease : Radiological changes after 6 and 12 months of treatment. / Robinson, P. J A; Walker, G. S.; Peacock, Munro; McLachlan, M. S F; Davison, A. M.

In: Clinical Radiology, Vol. 33, No. 1, 1982, p. 9-17.

Research output: Contribution to journalArticle

Robinson, P. J A ; Walker, G. S. ; Peacock, Munro ; McLachlan, M. S F ; Davison, A. M. / 1-Alpha-hydroxy vitamin D in dialysis bone disease : Radiological changes after 6 and 12 months of treatment. In: Clinical Radiology. 1982 ; Vol. 33, No. 1. pp. 9-17.
@article{0efa7c8db6c8407da1381a626668049a,
title = "1-Alpha-hydroxy vitamin D in dialysis bone disease: Radiological changes after 6 and 12 months of treatment",
abstract = "Biochemical, radiological and histological indicators of dialysis bone disease were studied before, 6 months (58 patients) and 12 months (48 patients) after starting treatment with 1α-OH D3. Radiographic healing of subperiosteal erosions was seen after 6 months in 60{\%} and after 12 months in 77{\%} of affected patients. Radiographic improvement, however, was not significantly related to reductions in resorptive surfaces seen on quantitative bone histology, nor to changes in plasma concentrations of immunoreactive parathyroid hormone. Metastatic calcification appeared or increased in 43{\%} of patients after 6 months and 52{\%} after 12 months. Periosteal new bone developed or increased in 14{\%} of patients after 6 months and 17{\%} after 12 months. Both metastatic calcification and periosteal new bone formation were associated with high plasma phosphate concentrations, but not with plasma calcium, alkaline phosphatase or parathyroid hormone concentrations. Treatment with 1α-OH D3 produces radiological improvement in the majority of patients with dialysis bone disease, but the lack of correlation with histological changes confirms the need for regular radiographic examination. Metastatic calcification and periosteal new bone formation probably represent toxicity of 1α-OH D3, but may be minimised by phosphate restriction.",
author = "Robinson, {P. J A} and Walker, {G. S.} and Munro Peacock and McLachlan, {M. S F} and Davison, {A. M.}",
year = "1982",
doi = "10.1016/S0009-9260(82)80330-9",
language = "English (US)",
volume = "33",
pages = "9--17",
journal = "Clinical Radiology",
issn = "0009-9260",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - 1-Alpha-hydroxy vitamin D in dialysis bone disease

T2 - Radiological changes after 6 and 12 months of treatment

AU - Robinson, P. J A

AU - Walker, G. S.

AU - Peacock, Munro

AU - McLachlan, M. S F

AU - Davison, A. M.

PY - 1982

Y1 - 1982

N2 - Biochemical, radiological and histological indicators of dialysis bone disease were studied before, 6 months (58 patients) and 12 months (48 patients) after starting treatment with 1α-OH D3. Radiographic healing of subperiosteal erosions was seen after 6 months in 60% and after 12 months in 77% of affected patients. Radiographic improvement, however, was not significantly related to reductions in resorptive surfaces seen on quantitative bone histology, nor to changes in plasma concentrations of immunoreactive parathyroid hormone. Metastatic calcification appeared or increased in 43% of patients after 6 months and 52% after 12 months. Periosteal new bone developed or increased in 14% of patients after 6 months and 17% after 12 months. Both metastatic calcification and periosteal new bone formation were associated with high plasma phosphate concentrations, but not with plasma calcium, alkaline phosphatase or parathyroid hormone concentrations. Treatment with 1α-OH D3 produces radiological improvement in the majority of patients with dialysis bone disease, but the lack of correlation with histological changes confirms the need for regular radiographic examination. Metastatic calcification and periosteal new bone formation probably represent toxicity of 1α-OH D3, but may be minimised by phosphate restriction.

AB - Biochemical, radiological and histological indicators of dialysis bone disease were studied before, 6 months (58 patients) and 12 months (48 patients) after starting treatment with 1α-OH D3. Radiographic healing of subperiosteal erosions was seen after 6 months in 60% and after 12 months in 77% of affected patients. Radiographic improvement, however, was not significantly related to reductions in resorptive surfaces seen on quantitative bone histology, nor to changes in plasma concentrations of immunoreactive parathyroid hormone. Metastatic calcification appeared or increased in 43% of patients after 6 months and 52% after 12 months. Periosteal new bone developed or increased in 14% of patients after 6 months and 17% after 12 months. Both metastatic calcification and periosteal new bone formation were associated with high plasma phosphate concentrations, but not with plasma calcium, alkaline phosphatase or parathyroid hormone concentrations. Treatment with 1α-OH D3 produces radiological improvement in the majority of patients with dialysis bone disease, but the lack of correlation with histological changes confirms the need for regular radiographic examination. Metastatic calcification and periosteal new bone formation probably represent toxicity of 1α-OH D3, but may be minimised by phosphate restriction.

UR - http://www.scopus.com/inward/record.url?scp=0020030668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020030668&partnerID=8YFLogxK

U2 - 10.1016/S0009-9260(82)80330-9

DO - 10.1016/S0009-9260(82)80330-9

M3 - Article

C2 - 6802550

AN - SCOPUS:0020030668

VL - 33

SP - 9

EP - 17

JO - Clinical Radiology

JF - Clinical Radiology

SN - 0009-9260

IS - 1

ER -